Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryAug052020	Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy , for AML and Multiple Myeloma IND Cleared Read All »	View HTML
Toggle SummaryAug062019	Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor Combination Arm in Solid Tumor Study Successfully Completed FT516 GMP Production and Product Release for Initiation of First-ever Clinical Trial of Engineered iPSC-derived Cell Read All »	View HTML
Toggle SummaryAug062018	Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product FT500 Licensed Novel CAR Constructs from Memorial Sloan Kettering Cancer Center for Off-the-Shelf Read All »	View HTML
Toggle SummaryAug142017	Fate Therapeutics Reports Second Quarter 2017 Financial Results First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy Company Convenes PROTECT Data Monitoring Committee for ProTmune™ Read All »	View HTML Fate Therapeutics Reports Second Quarter 2017 Financial Results 37.5 KB
Toggle SummaryAug082016	Fate Therapeutics Reports Second Quarter 2016 Financial Results Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for 2016 Announced $10.3 Million Common Stock Private Placement SAN DIEGO, Aug. Read All »	View HTML Fate Therapeutics Reports Second Quarter 2016 Financial Results 38.3 KB
Toggle SummaryAug052015	Fate Therapeutics Reports Second Quarter 2015 Financial Results Interim Data From PROHEMA® PUMA Study Show Reduction in Severe Infections Across Multiple Pathogen Types First Pediatric Subject Treated in PROHEMA® PROVIDE Study of CNS Cellular Replacement Strategic Research Collaboration Formed With Juno Therapeutics to Identify Small Molecule Read All »	View HTML Fate Therapeutics Reports Second Quarter 2015 Financial Results 38.5 KB
Toggle SummaryAug122014	Fate Therapeutics Reports Second Quarter 2014 Financial Results First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initiate in 2H14 SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the Read All »	View HTML Fate Therapeutics Reports Second Quarter 2014 Financial Results 29.6 KB
Toggle SummaryDec042020	Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma 3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host Disease Six Doses of Read All »	View HTML
Toggle SummaryDec132023	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, Read All »	View HTML
Toggle SummaryFeb022024	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.